Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Free Cash Flow (2016 - 2025)

Mimedx (MDXG) has disclosed Free Cash Flow for 15 consecutive years, with $24.7 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 26.85% to $24.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.0 million through Dec 2025, up 11.5% year-over-year, with the annual reading at $73.0 million for FY2025, 11.5% up from the prior year.
  • Free Cash Flow hit $24.7 million in Q4 2025 for Mimedx, down from $29.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $29.1 million in Q3 2025 to a low of -$10.3 million in Q1 2022.
  • Historically, Free Cash Flow has averaged $7.8 million across 5 years, with a median of $4.9 million in 2023.
  • Biggest five-year swings in Free Cash Flow: tumbled 383.5% in 2022 and later soared 14748.48% in 2024.
  • Year by year, Free Cash Flow stood at -$3.6 million in 2021, then soared by 202.05% to $3.6 million in 2022, then surged by 352.67% to $16.4 million in 2023, then rose by 18.36% to $19.4 million in 2024, then rose by 26.85% to $24.7 million in 2025.
  • Business Quant data shows Free Cash Flow for MDXG at $24.7 million in Q4 2025, $29.1 million in Q3 2025, and $14.2 million in Q2 2025.